Mazibrada Jasenka, Jayatunge Nishani, Domecq Celine, Witkowski Leora, Croce Sabrina, Foulkes William D, McCluggage W Glenn
Department of Pathology, Norfolk and Norwich University Hospital, Norwich.
Cancer Research Program and the SCCOHT/SMARCA4 Registry and Biobank, Research Institute of the McGill University Health Centre, Montreal.
Am J Surg Pathol. 2023 Nov 1;47(11):1261-1266. doi: 10.1097/PAS.0000000000002088. Epub 2023 Jun 22.
Small cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) is a rare and aggressive ovarian neoplasm that is most common in the second and third decades. Molecular studies have established inactivating SMARCA4 alterations as the driver of SCCOHT, these being present in over 95% of these neoplasms. SMARCA4 alterations almost always result in loss of immunoreactivity with SMARCA4 (BRG1) antibody, and this is an extremely useful adjunct in the diagnosis of SCCOHT. Herein, we report 7 cases of SCCOHT (2 from the same patient) with retention of nuclear immunoreactivity with SMARCA4, but with SMARCA4 alterations identified on molecular testing. All cases exhibited loss of SMARCA2 (BRM) immunoreactivity. In addition, following the identification of diffuse TLE1 immunoreactivity in one of these cases (which did not exhibit an SS18 gene rearrangement characteristic of synovial sarcoma), we stained a total of 63 cases of SCCOHT (14 on whole tissue sections: 49 on tissue microarray) with this marker and 7 of 14 (50%) and 22 of 49 (45%) were positive on whole sections and tissue microarray, respectively. Most cases were focally positive but occasional cases exhibited diffuse immunoreactivity. Our observations highlight the importance of SMARCA2 immunohistochemical staining and molecular testing in suspected cases of SCCOHT that exhibit retained SMARCA4 immunoreactivity. Th common expression of TLE1 in these neoplasms represents a potential diagnostic pitfall since synovial sarcoma may be considered in the differential, especially in cases with retained SMARCA4 immunohistochemistry.
高钙血症型卵巢小细胞癌(SCCOHT)是一种罕见且侵袭性强的卵巢肿瘤,最常见于第二和第三个十年。分子研究已确定失活性SMARCA4改变是SCCOHT的驱动因素,超过95%的此类肿瘤存在这些改变。SMARCA4改变几乎总是导致与SMARCA4(BRG1)抗体的免疫反应性丧失,这在SCCOHT的诊断中是一项极其有用的辅助手段。在此,我们报告7例SCCOHT(其中2例来自同一患者),其细胞核与SMARCA4保持免疫反应性,但分子检测发现存在SMARCA4改变。所有病例均表现出SMARCA2(BRM)免疫反应性丧失。此外,在其中1例病例中发现弥漫性TLE1免疫反应性(该病例未表现出滑膜肉瘤特征性的SS18基因重排)后,我们用该标志物对总共63例SCCOHT病例(14例在全组织切片上:49例在组织芯片上)进行染色,全组织切片上14例中有7例(50%)呈阳性,组织芯片上49例中有22例(45%)呈阳性。大多数病例为局灶性阳性,但偶尔有病例表现为弥漫性免疫反应性。我们的观察结果强调了在疑似SCCOHT病例中,当SMARCA4免疫反应性保留时,SMARCA2免疫组化染色和分子检测的重要性。TLE1在这些肿瘤中的常见表达代表了一个潜在的诊断陷阱,因为在鉴别诊断中可能会考虑滑膜肉瘤,尤其是在SMARCA4免疫组化保留的病例中。